TCR-engineered T Cells in Solid Tumors (ACTengine)
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Relapsed and/or Refractory Solid Tumors (ACTengine IMA203-101)
MD Anderson Cancer Center researchers seek patients with solid tumors to trial a new gene-modified stem cell transplant (autologous) which uses a new technology to genetically modify their immune T-cells to attack their tumor. This investigational immunotherapy is customized to the patient.
The treatment will require leukapheresis to collect the T-cells for gene modification, chemotherapy before they are re-infused, and proleukin drugs to help the cells grow. Follow up, including lab and imaging assessments, may continue for up to 12 months.
- Be 18 years of age or older
- Have pathologically confirmed advanced and/or metastatic solid tumor
- Have life expectancy more than 3 months
THE STUDY INVOLVES:
- Screening to confirm acceptance to the study.
- Leukapheresis to collect the patient’s own stem cells, which will be gene-modified in the lab (no treatment during that period) to target cancer cells.
- Admission to the study center and a course of chemotherapy.
- Infusion of the gene-modified stem cells, followed by aldesleukin/proleukin to promote their growth.
- Follow up, including lab and imaging assessments, may continue for up to 12 months.
LOCATIONS & CONTACTS:
The study site is at the University of Texas MD Anderson Cancer Center in Houston, TX Map.
Jorge Rivas, M.D. | 346-204-5350 | [email protected]
Immatics US, Inc.
M.D. Anderson Cancer Center
Or go online: